Showing results (701-710 of 725) with videos related to

Sort By:
Pageof 73
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2022
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)Janos L Tanyi, Leslie M Randall, Setsuko K Chambers, et al.
Cancer Medicine|November 27, 2019
Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE)Patricia M Livingston, Leila Heckel, Liliana Orellana, et al.
European Urology|November 13, 2013
A progress report on a prospective randomised trial of open and robotic prostatectomyRobert A Gardiner, Geoffrey D Coughlin, John W Yaxley, et al.
Scientific Reports|May 25, 2023
Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcomaHajime Asada, Akiyoshi Tani, Hiroki Sakuma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2018
MSR1 repeats modulate gene expression and affect risk of breast and prostate cancerA M Rose, A Krishan, C F Chakarova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerSetsuko K Chambers, Mary C Clouser, Amanda F Baker, et al.
The Journal of Biological Chemistry|May 16, 2000
Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3P G Szekeres, A I Muir, L D Spinage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerBeth Y Karlan, Amit M Oza, Gary E Richardson, et al.
The Journal of Biological Chemistry|December 24, 2002
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acidsCelia P Briscoe, Mohammad Tadayyon, John L Andrews, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2024
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapyChristof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, et al.
Pageof 73